The Tinzaparin (a low-molecular-weight heparin) can trigger tissue factor pathway inhibitor (TFPI) secretion from cancer cells, and also the recombinant TFPI induce suppression of tumor-derived exosomes causing migration of tumor cells (Gamperl et al., 2016). Here, TFPI is linked to neoplasm.